| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
HIV agents which can eliminate latent HIV virus, are expected as the next generation anti-HIV drug. In this study, we established the isolation and purification method of Gnidimacrin, a daphnane-type diterpenoid from Stellera chamaejasme, which shows extremely potent anti-HIV activity against latent HIV virus. In addition, we clarified the effectiveness of Gnidimacrin for the elimination of latent HIV-1 in an ex vivo model using peripheral blood mononuclear cells from patients with HIV infection. Furthermore, the chemically synthesized derivatives of Gnimacrin were evaluated for their in vitro anti-HIV activities. As a result, the acyl group at the 3-position of gnidimacrin is important for the anti-HIV activity, whereas the 2'-position hydroxyl group is an important functional group for further investigation of the mechanism of Gnidimacrin action.
|
